These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 940666)

  • 41. [Natural killer cell activity and tissue distribution in malignant lymphoma].
    Nishikori M; Kobayashi E; Doi S; Kamesaki H; Kita K; Fukuhara S; Miki M; Uchino H; Yamabe H
    Rinsho Ketsueki; 1985 Jun; 26(6):916-23. PubMed ID: 4068252
    [No Abstract]   [Full Text] [Related]  

  • 42. [Passive transmission of the tuberculin allergy in sarcoidosis and in malignant lymphomas].
    Kohout J
    Wien Klin Wochenschr; 1967 Oct; 79(43):795-8. PubMed ID: 4872281
    [No Abstract]   [Full Text] [Related]  

  • 43. [Clincal study on serum immunoglobulin E (IgE) concentrations in patients with malignant lymphoma with special reference to Hodgkin's disease (author's transl)].
    Kimura I; Onoshi T; Tanizaki Y; Ueda N
    Rinsho Ketsueki; 1975 Dec; 16(12):1117-23. PubMed ID: 1240980
    [No Abstract]   [Full Text] [Related]  

  • 44. [Tuberculin allergy and malignant diseases].
    Chollet P; Rey M
    Nouv Presse Med; 1973 Feb; 2(6):381. PubMed ID: 4569123
    [No Abstract]   [Full Text] [Related]  

  • 45. [Presence of cells with a high content of DNA in the circulating blood of 2 patients with malignant lymphoma. Blastic response of blood lymphocytes to PHA].
    Chilosi M; Nigro M
    Pathologica; 1974; 66(957-958):287-93. PubMed ID: 4453436
    [No Abstract]   [Full Text] [Related]  

  • 46. Blastogenic transformation of lymphocytes following phytohaemagglutinin treatment in vitro in malignant lymphomas. II. Reticulosarcoma. (Correlation with the immunity reaction of the cellular type and the clinical status).
    Libánský J; Sedlácková M; Pinosová I
    Neoplasma; 1973; 20(1):61-7. PubMed ID: 4573872
    [No Abstract]   [Full Text] [Related]  

  • 47. [Immunity and hypersensitivity in Hodgkin's lymphoma].
    Leoni P; Marchegiani G; Montillo M; Centurioni R; Montroni M; Danieli G
    Minerva Med; 1982 May; 73(20):1361-9. PubMed ID: 6210855
    [No Abstract]   [Full Text] [Related]  

  • 48. [Cellular immunity using skin tests in children with malignant diseases at the time of diagnosis and after therapy].
    Göbel U; Körholz D; Janssen G; Schwamborn D; Jürgens H
    Onkologie; 1987 Jun; 10(3 Suppl):4-7. PubMed ID: 3309761
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Monoclonal immunoglobulin in patients with malignant lymphoma].
    Chu DT
    Zhonghua Zhong Liu Za Zhi; 1986 Jan; 8(1):16-9. PubMed ID: 3732019
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Implications of persistent T cell abnormalities for the etiology of Hodgkin's disease.
    Fisher RI
    Cancer Treat Rep; 1982 Apr; 66(4):681-7. PubMed ID: 6210434
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relation of cell-mediated immunity to staging, histology and prognosis in untreated patients with Hodgkin's disease.
    De Gast GC; Halie MR
    Neth J Med; 1976; 19(4-5):196-200. PubMed ID: 980187
    [No Abstract]   [Full Text] [Related]  

  • 52. [Immunological aspects of Hodgkin's disease].
    Bianchini E
    Minerva Med; 1975 Feb; 66(8):365-70. PubMed ID: 1078722
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Study of cell mediated immunity in Hodgkin's disease (apropos of 30 cases)].
    Laurens A; Morin A; Aubry J; Laurent G; Audreu G; Hainaut J
    Ann Med Interne (Paris); 1975 Dec; 126(12):829-36. PubMed ID: 1225093
    [No Abstract]   [Full Text] [Related]  

  • 54. [Reactivity of the skin to bacterial antigens in malignant lymphogranulomatosis].
    Rasiewicz W; Kardaszewicz E
    Przegl Dermatol; 1969; 56(2):153-8. PubMed ID: 5790573
    [No Abstract]   [Full Text] [Related]  

  • 55. [Surface antigen of hepatitis B in malignant lymphoma (author's transl)].
    Planes N; De Somoza N; Morgenfeld MC
    Sangre (Barc); 1976; 21(3):492-8. PubMed ID: 968714
    [No Abstract]   [Full Text] [Related]  

  • 56. [Acquired immunologic deficiencies].
    Kaboth W
    Med Klin; 1970 Oct; 65(43):1862-6. PubMed ID: 4394476
    [No Abstract]   [Full Text] [Related]  

  • 57. [Activation of the immune system and remission period in malignant lymphomas].
    Havemann K; Schultz H
    Hamatol Bluttransfus; 1976; 18():329-38. PubMed ID: 964711
    [No Abstract]   [Full Text] [Related]  

  • 58. [Humoral and cellular immunologic deficiency in lymphogranulomatosis].
    Patakfalvy A; Balázs M; Simon K; Gógl A; Kovács Z
    Orv Hetil; 1972 Nov; 113(45):2704-7. PubMed ID: 5083235
    [No Abstract]   [Full Text] [Related]  

  • 59. [Malignant lymphoma--from the view of the clinician].
    Rák K
    Orv Hetil; 1988 Dec; 129(51):2723-7. PubMed ID: 3064022
    [No Abstract]   [Full Text] [Related]  

  • 60. [Serum immunoglobulins in patients with malignant lymphomas].
    Zhuravlev VS; Vashurina EA; Orlova LD; Kolpikova LA; Mokeeva RA
    Probl Gematol Pereliv Krovi; 1982 Mar; 27(3):22-4. PubMed ID: 6806801
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.